Shares of AtriCure (NASDAQ: ATRC) plummeted 10.01% in pre-market trading on Wednesday following the company's first quarter 2025 earnings report and subsequent analyst price target cuts. The medical device maker continues to face headwinds in its minimally invasive (MIS) ablation business due to competition from pulsed field ablation (PFA) technologies.
AtriCure reported Q1 revenue of $123.6 million, up 13.6% year-over-year, with strong performance in pain management and appendage management franchises. However, the company's US MIS ablation sales declined approximately 31% compared to the prior year period. CEO Michael Carrel acknowledged ongoing pressure in this segment, stating, "We anticipate that is going to happen for the rest of the year."
Following the earnings release, multiple analysts lowered their price targets on AtriCure stock. Needham cut its target to $44 from $51, while UBS reduced its target to $58 from $60. The company maintained its full-year 2025 revenue guidance of $517 million to $527 million but raised its adjusted EBITDA outlook, suggesting efforts to improve profitability amid challenges in the MIS ablation market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。